Cha Biotech Obtains European Patent for Stem Cell Isolation and Cultivation Technology

[Asia Economy Reporter Chunhee Lee] Cha Biotech announced on the 14th that it has obtained a European patent for a method of isolating stem cells from umbilical cord tissue and the scope of application of therapeutics developed using these cells. This technology cultivates umbilical cord-derived stem cells in an environment similar to the human body to proliferate a higher purity of cells, thereby improving the manufacturing efficiency of the cells.

Following the acquisition of a Japanese patent for the ‘method of manufacturing umbilical cord-derived stem cells with improved manufacturing efficiency,’ Cha Biotech has now established a global patent portfolio with this European patent acquisition.

Umbilical cord-derived stem cells are evaluated to be useful for treating various diseases because they express higher levels of key factors that directly act on immune regulation and nerve regeneration compared to adult bone marrow-derived stem cells, which are commonly used in existing stem cell therapeutics. Based on its proprietary cultivation technology, Cha Biotech has the capacity to produce stem cell therapeutics sufficient for tens of thousands of patients from a single tissue. Additionally, through cell freezing technology, the cell viability period can be significantly extended, providing commercialization competitiveness to supply low-cost, high-efficiency stem cell therapeutics.

Cha Biotech CEO Sanghoon Oh said, "With this patent acquisition, we have established a foothold for entering the European market with umbilical cord-derived stem cell therapeutics," and added, "We will actively secure global partners for entry into the European and U.S. markets as well as domestic product approval."

This content was produced with the assistance of AI translation services.